NCM
Nantahala Capital Management Portfolio holdings
AUM
$1.41B
This Quarter Return
+7.55%
1 Year Return
+32.9%
3 Year Return
+104.34%
5 Year Return
+145.08%
10 Year Return
+443.66%
AUM
$999M
AUM Growth
+$999M
(+27%)
Cap. Flow
+$107M
Cap. Flow
% of AUM
10.73%
Top 10 Holdings %
Top 10 Hldgs %
44.45%
Holding
134
New
12
Increased
32
Reduced
54
Closed
15
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$99.2M |
| 2 |
Evolus
EOLS
|
$26.2M |
| 3 |
RDNW
RideNow Group, Inc. Class B Common Stock
RDNW
|
$22.9M |
| 4 |
iShares Russell 2000 ETF
IWM
|
$15.3M |
| 5 |
Establishment Labs
ESTA
|
$15.1M |
Top Sells
| 1 |
Pathward Financial
CASH
|
$9.24M |
| 2 |
Cytokinetics
CYTK
|
$5.78M |
| 3 |
RH
RH
|
$5.51M |
| 4 |
Immatics
IMTX
|
$5.34M |
| 5 |
Ventyx Biosciences
VTYX
|
$5.13M |
Sector Composition
| 1 | Healthcare | 59.27% |
| 2 | Consumer Discretionary | 14.15% |
| 3 | Financials | 7.37% |
| 4 | Communication Services | 5.83% |
| 5 | Technology | 4.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
The RMR Group
RMR
$279M
| $11.4M | 0.68% |
404,063
-27,970
| -6% | -$790K |
|
27
Abeona Therapeutics
ABEO
$356M
| $11.3M | 0.67% |
2,250,252
-47,542
| -2% | -$238K |
|
28
Reservoir Media
RSVR
$513M
| $11.1M | 0.66% |
1,550,797
+564,469
| +57% | +$4.02M |
|
|
ABVX
29
Abivax
ABVX
$6.32B
| $10.8M | 0.65% |
+1,010,034
| New | +$10.8M |
|
30
Tourmaline Bio
TRML
$645M
| $10.8M | 0.64% |
410,907
-2,542,222
| -86% | +$3.03M |
|
|
ILPT
31
Industrial Logistics Properties Trust
ILPT
$389M
| $9.37M | 0.56% |
1,992,819
-364,465
| -15% | -$1.71M |
|
32
VistaGen Therapeutics
VTGN
$113M
| $9.34M | 0.56% |
+1,816,730
| New | +$9.34M |
|
|
33
Cytokinetics
CYTK
$5.98B
| $9.19M | 0.55% |
110,017
-69,240
| -39% | -$5.78M |
|
34
Amylyx Pharmaceuticals
AMLX
$877M
| $9.13M | 0.55% |
620,110
+212,905
| +52% | +$3.13M |
|
35
Payoneer
PAYO
$2.44B
| $9.1M | 0.54% |
1,747,404
+134,542
| +8% | +$701K |
|
36
ARS Pharmaceuticals
SPRY
$1.08B
| $8.75M | 0.52% |
1,596,504
+497,429
| +45% | +$2.73M |
|
37
eHealth
EHTH
$126M
| $8.65M | 0.52% |
991,821
+191,821
| +24% | +$1.67M |
|
38
Dyne Therapeutics
DYN
$1.92B
| $8.55M | 0.51% |
642,789
-40,375
| -6% | -$537K |
|
39
Assertio
ASRT
$78M
| $8.15M | 0.49% |
7,619,440
+2,949,440
| +63% | +$3.16M |
|
40
Syndax Pharmaceuticals
SNDX
$1.39B
| $7.89M | 0.47% |
365,259
+125,228
| +52% | +$2.71M |
|
41
Tarsus Pharmaceuticals
TARS
$2.44B
| $7.6M | 0.45% |
375,276
+239,776
| +177% | +$4.86M |
|
42
TELA Bio
TELA
$65.4M
| $7.27M | 0.43% |
1,097,866
+641,774
| +141% | +$4.25M |
|
43
DHI Group
DHX
$146M
| $6.84M | 0.41% |
2,639,687
-58,514
| -2% | -$152K |
|
44
DXP Enterprises
DXPE
$1.89B
| $6.8M | 0.41% |
201,829
+21,842
| +12% | +$736K |
|
45
Reading International Class A
RDI
$35.2M
| $6.5M | 0.39% |
3,402,203
+526,163
| +18% | +$1M |
|
46
InspireMD
NSPR
$101M
| $5.81M | 0.35% |
2,066,456
+298,406
| +17% | +$839K |
|
47
NN Inc
NNBR
$123M
| $5.63M | 0.34% |
1,407,222
+54,079
| +4% | +$216K |
|
48
AN2 Therapeutics
ANTX
$35.3M
| $5.09M | 0.3% |
248,278
-108,511
| -30% | -$2.22M |
|
49
IDEAYA Biosciences
IDYA
$2.26B
| $4.96M | 0.3% |
139,298
-6,562
| -4% | -$233K |
|
|
AGS
50
DELISTED
PlayAGS
AGS
| $4.78M | 0.29% |
566,588
-27,986
| -5% | -$236K |
|